We cut '25e-'27e adj. EBITA by 13-1% Gross profit per consultant at normal levels in '26e '25e EV/EB...
'25e-'27e EBITA down 13-8% Adverse impact from stronger SEK '25e EV/EBITA ~8x, ~50% below peers Wha...
Minor estimate changes Q1e: 2% organic growth and margin improvements Trading at NTM EV/EBITA of ~8x...
FX-driven estimate changes Direct tariff impact likely minor NTM EV/EBIT of just below 7x What to l...
Q1e sales flat q-o-q, slight margin improvement to 5.
Q1e sales -2% y-o-y, orders +10%, adj. EBITA margin 6.
We estimate -2% organic growth and -22% adj. EBITA y-o-y in Q1e BlakYaks adds to the UK business and...
Q1 report Thursday, 24 April at 12:00 CET '25e-'27e EBITA down 3%; 6% CAGR in '24-'27e 11-9x EBITA i...
Analysguiden räknar med en fortsatt fallande vinst under Q1 2025 primärt drivet av en svagare margin...
Irisity AB (“Irisity” or “the Company”) is a leading provider of AI-driven video analytics solutions...
Redeye provides a preview of SSH's Q1 results set to be released on April 29.
Redeye gives a short initial comment on the positive news that Leqembi has been approved in the EU.
Beijer Alma inleder året med tre nya förvärv och inför Q1-rapporten räknar Analysguiden med en stabi...
Redeye provides a short research update following Alzinova’s recent rights issue of approximately SE...
Hyresintäkterna uppgick till 865 mkr, i linje med motsvarande kvartal föregående år.
Q-linea has improved access to growth capital and recently advanced the ASTar launch in Europe , the...
Redeye comments on Faron’s announcement that the phase II BEXMAB trial has met its primary endpoint ...
AVTECH presented its Q1 2025 figures, which closely aligned with Redeye’s projections for net sales,...
Last evening, Enviro announced it had resolved a partially guaranteed rights issue of units of appro...
Q1e: a solid quarter with EBITA up 11% y-o-y Higher estimates following ambitious new targets Medica...
